Table of Contents
- Trials overview
- Conditions and patient groups
- Trial phases and study designs
- What is measured in these trials
- Important patient points
- Selected trial examples
Trials overview
The trial data show that Vincristine Sulfate is being studied in many cancer research programs, especially in lymphoma and leukemia trials.[1] It is usually given as part of a multi-drug treatment plan, such as CHOP, R-CHOP, or other combination regimens, rather than as a stand-alone treatment.[2]
These studies are mainly trying to learn whether treatment plans that include Vincristine Sulfate can improve outcomes such as survival, remission, or response to therapy, while also checking safety and tolerability.[3] Several trials compare a new treatment strategy with standard care or investigator’s choice treatment.[4]
Conditions and patient groups
The most common conditions are diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and acute lymphoblastic leukemia.[5] Other studies include Ewing sarcoma, neuroblastoma, retinoblastoma, medulloblastoma, hepatoblastoma, hepatocellular carcinoma, rhabdomyosarcoma, and ependymoma.[6]
The patient groups are varied. Some trials are for children only, some for adults, some for older adults, and some for people of any age with a specific cancer type.[7] Several studies focus on special groups such as newly diagnosed patients, relapsed or refractory patients, high-risk disease, or people who are not fit for full-intensity treatment.[8]
Trial phases and study designs
The studies include Phase 1, Phase 2, Phase 3, and Phase 4 trials.[9] Phase 1 studies in the data mainly focus on dose-finding, safety, and the recommended phase II dose, while later phases compare how well treatment works and how safe it is in larger groups.[6]
Many trials are randomized, which means participants are assigned by chance to different treatment groups.[10] Some trials are open-label, meaning both the study team and the participant know which treatment is being given.[6]
What is measured in these trials
The main endpoints often measure how long the cancer stays controlled, such as progression-free survival, event-free survival, and disease-free survival.[11] Other common endpoints include complete response, complete metabolic response, overall response rate, and minimal residual disease negativity.[12]
Some trials also measure safety outcomes, including dose-limiting toxicities, treatment-emergent adverse events, serious adverse events, and changes in laboratory tests or vital signs.[13] In a few studies, the endpoint is more specific, such as failure-free survival, treatment-related morbidity, or eye preservation in retinoblastoma.[14]
Important patient points
Combination treatment: In nearly all listed studies, Vincristine Sulfate is one drug in a larger treatment plan, so the trial is testing the whole plan, not just one medicine.[15]
Different age groups: The studies include infants, children, teens, adults, and older adults, so the age range depends on the cancer and the protocol.[16]
Different disease stages: Some trials are for newly diagnosed disease, while others are for relapsed, refractory, high-risk, or untreated advanced disease.[17]
Special review methods: Some results are checked by an independent review committee or central review to make the assessment more consistent and fair.[18]
Selected trial examples
In one large Phase 3 lymphoma study in previously untreated high-risk large B-cell lymphoma, the main outcome is progression-free survival, meaning the time until the disease gets worse or the person dies.[1] In another Phase 3 study in untreated follicular lymphoma, the primary outcomes include safety measures in the safety run-in part and complete response at 30 months in the randomized part.[4]
In pediatric and young adult cancer research, Vincristine Sulfate appears in trials for acute lymphoblastic leukemia, Ewing sarcoma, neuroblastoma, retinoblastoma, and medulloblastoma, with outcomes such as event-free survival, overall survival, and response rates.[6][11] These studies show that Vincristine Sulfate remains an important part of combination treatment research across both blood cancers and childhood solid tumors.[19]
